Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024)

Artiva Biotherapeutics (ARTV) posted quarterly Revenue of $251000.0 for Q1 2024, down 89.32% quarter-over-quarter from $2.4 million in Q4 2023.

Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported Revenue for 2 consecutive years, with $251000.0 the latest figure, recorded in Q1 2024.

In Q1 2024, Revenue changed N/A year-over-year to $251000.0; the TTM figure through Dec 2024 stood at $251000.0 (changed N/A YoY), while the FY2024 annual figure was $251000.0, down 99.25% from the prior year.
Revenue fell to $251000.0 in Q1 2024 per ARTV's latest filing, from $2.4 million in the prior quarter.
Across five years, Revenue topped out at $26.7 million in Q3 2023 and bottomed at $251000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Artiva Biotherapeutics	451.28 Mn	451.28 Mn	-	-

Download Data